Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233193 | 0.80 | MAPT (0.40) | — | |
| SCHEMBL4721672 | 0.80 | TSHR (0.30) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL854160 | 0.80 | MAPK1 (0.31) | — | |
| SCHEMBL715395 | 0.78 | — | — | |
| SCHEMBL752438 | 0.77 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6040299 | 0.77 | — | — | |
| SCHEMBL4585453 | 0.76 | TSHR (0.33) | — | |
| SCHEMBL2915925 | 0.75 | — | — | |
| SCHEMBL1938997 | 0.75 | ALDH1A1 (0.38) | — | |
| SCHEMBL7787553 | 0.74 | KMT2A (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | claimed |
| JP-2011529037-A | — | — | 2011-12-01 | — | — | JP | claimed |
| EP-2310357-A1 | POTASSIUM ION CHANNEL MODULATORS&USES THEREOF | Ramot at Tel Aviv University Limited (IL) | 2011-04-20 | — | — | EP | claimed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | claimed |
| WO-2010010380-A1 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | WO | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| EP-0438230-B1 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME (GB) | 1997-04-23 | — | — | EP | claimed |
| US-4680301-A | 6-isothiocyanato-2,5-substituted benzothiazoles or benzoxazoles useful as anthelmintic effective agents | CIBA-GEIGY CORPORATION (US) | 1987-07-14 | — | — | US | claimed |
| EP-2814822-B1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| WO-2013120921-A9 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| US-5208248-A | Hydroxytryptamine Receptor Agonists | MERCK SHARPE & DOHME, LTD. (GB) | 1993-05-04 | — | — | US | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0494774-A1 | Indazole-substituted fivemembered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1992-07-15 | — | — | EP | disclosed |
| EP-0438230-A2 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | CHRNB2 4404/4885CHRNA4 4704/4885CHRNB4 4450/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CHRNB2 2161/4885CHRNA4 2476/4885CHRNB4 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.